BIOMARIN PHARMACEUTICAL INC
Form 8-K
September 11, 2001

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
September 11, 2001 (September 6, 2001)

BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)

Delaware	000-26727	68-0397820
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

371 Bel Marin Keys Boulevard,
Suite 210
Novato, California
(Address of principal executive offices)

94949
(Zip Code)

(415) 884-6700
(Registrant's telephone number, including area code)

Item 5. Other Events

Effective September 6, 2001, Ansbert Gadicke, MD, has resigned from the Board of Directors of BioMarin. Dr. Gadicke is the Managing Director of MPM Capital LLC and served as a member of the BioMarin Board of Directors since December 1997. MPM Capital is the beneficial holder of 3,212,560 shares or 7.6 % of BioMarin's common stock. The Board elected Phyllis Gardner, MD, Senior Associate Dean for Education and Student Affairs, Stanford University School of Medicine, to take Dr. Gadicke's position on the Board.

Item 7. Financial Statements and Exhibits

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.

By: /s/ Raymond W. Anderson

Raymond W. Anderson
Chief Operating Officer, Chief Financial Officer, Secretary and Vice President Finance and Administration

Date: September 11, 2001